Our supporters

Home Our supporters

GUIDE.MRD is a people-centered precision oncology project designed to improve the utility and clinical implementation of ctDNA as biomarker of MRD to predict clinical response and choice of multi-modal therapy for patients with solid tumour malignancies. Partners from academic, medical technology, pharmaceutical and patient advocacy sectors assembled the project objectives to be fully pertinent and aligned with HORIZON-JU-IHI-2022-01, Call 1, Topic 3 “Personalized oncology: innovative people centered, multi-modal therapies against cancer”.

Project details

Start date: 01/05/2023
Duration: 60 months
Total cost: €34.4 million
Project Coordinator: Klaus Pantel (UKE)
Project Leader: Maria Karasarides (BMS)

Our objectives

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066.
The JU receives support from the European Union’s Horizon Europe research and innovation programme and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics INC.
Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.